After one false alarm, Rigel Pharmaceuticals has officially won FDA approval for its lead rare disease therapy, Tavalisse.
Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.
Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.
Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.
It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.
Merck needed a big win in melanoma to help it try to catch up to archrival Bristol-Myers Squibb. And over the weekend, it got one.
While consumers are all abuzz about the Facebook data scandal, pharma companies don't need to scramble. Just keep an eye open.
Thermo Fisher features its employees and the patients they help in a new campaign that personalizes its drug development and delivery services.
Merck has put up some monster Keytruda-chemo combo numbers that'll raise the bar for rivals looking to steal the class crown.
In February, BMS tallied a lung cancer win for its immuno-oncology combo. But one question remained: Was the win big enough to keep it competitive?